Gwangju, South Korea

H S Pagire

This inventor holds 1 USPTO granted patent. Top assignees: Gwangju Institute of Science and Technology, Yonsei University. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: H S Pagire. Retrieved from https://idiyas.com/inventor/h-s-pagire

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: H S Pagire: Innovator in Autophagy Enhancement

Introduction

H S Pagire is a notable inventor based in Gwangju, South Korea. He has made significant contributions to the field of metabolic disease treatment through his innovative research and patenting activities. His work focuses on enhancing autophagy, a crucial process in cellular health.

Latest Patents

H S Pagire holds a patent for an "Autophagy enhancer and use thereof." This patent includes a compound represented by chemical formulas 1 or 2, which can be effectively used in the prevention or treatment of metabolic diseases such as type 2 diabetes, insulin resistance, and obesity. The mechanism of action is based on the activation of autophagy through the promotion of lysosome production.

Career Highlights

Throughout his career, H S Pagire has been associated with prestigious institutions, including the Gwangju Institute of Science and Technology and Yonsei University. His work at these institutions has allowed him to explore and develop innovative solutions to pressing health issues.

Collaborations

H S Pagire has collaborated with notable colleagues, including Hyejin Lim and Myung-Shik Lee. Their joint efforts have contributed to advancing research in the field of metabolic diseases and autophagy.

Conclusion

H S Pagire's contributions to the field of autophagy enhancement highlight his role as an innovator in medical research. His patent and collaborative efforts reflect a commitment to improving health outcomes for individuals affected by metabolic diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…